Marie-Paule Kieny of the Drugs for Neglected Diseases Initiative is on a mission to remind stakeholders and governments that there is a moral imperative to pursue the fight against neglected diseases, as she tells LSIPR.
Marie-Paule Kieny’s accomplishments in the life sciences sector are impressive to say the least.
During her time as assistant director general, health systems and innovation at the World Health Organization (WHO), her most notable achievements included bringing coherence to WHO’s work on health systems to support member states progressing towards Universal Health Coverage and successfully leading the work of WHO on research and development (R&D) against Ebola from 2014 to 2016.
Her other triumphs at WHO include the development and licensing of new vaccines against bacterial meningitis, as well as addressing the global supply of pandemic influenza vaccine through technology transfer and manufacturing, with a focus on developing countries.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
Marie-Paule Kieny, Drugs for Neglected Diseases Initiative, LSIPR 50, World Health Organisation, vaccines, disease, developing countries, drug shortage